ReviewThrombosis research2020
The gut microbiome and thromboembolism.
Review in Thrombosis research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 75 citations in OpenAlex.
- Article
- Genetic and biological determinants of pulmonary embolism: Insights from Mendelian randomization studies.World journal of experimental medicine · 2026Review
- Gut Microbiota Dysbiosis and Risk of Venous Thromboembolism: A Systematic Review.Microorganisms · 2026Review
- Venous Thromboembolism and Gut Dysbiosis: Mechanistic Links Between Endotoxemia, Microbial Metabolites, and Thromboinflammation.Nutrients · 2026Review
- Article
- Pulmonary origin and risk assessment of cancer-associated thrombosis.Thrombosis journal · 2026Review
- The Gut-Heart Axis: A Comprehensive Review of Microbiota's Role in Cardiovascular Health and Disease and Emerging Therapeutic Strategies.Cardiology research and practice · 2026Review
- Evaluation of microbial-derived metabolites in patients with acute pulmonary embolism: findings from the MICTEP study.ERJ open research · 2025Article
- Cardiovascular Complications Are Increased in Inflammatory Bowel Disease: A Path Toward Achievement of a Personalized Risk Estimation.Journal of personalized medicine · 2025Article
- Huayu Qutan formula can improve platelet aggregation in acute coronary syndrome rats by regulating gut microbes to drive trimethylamine/flavin containing monooxygenase 3/trimethylamine N-oxide pathway.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Causal Relationship between Gut Microbiota and Pulmonary Embolism: An Analysis Using Mendelian Randomization.Polish journal of microbiology · 2025Article
- Article
- Is β2-glycoprotein I prothrombotic?Blood · 2025Article
- A mendelian randomization study on the association between 731 types of immune cells and 91 types of blood cells with venous thromboembolism.Thrombosis journal · 2025Article
- Analysis of gut and circulating microbiota characteristics in patients with liver cirrhosis and portal vein thrombosis.Frontiers in microbiology · 2025Article
- Decoding TMAO in the Gut-Organ Axis: From Biomarkers and Cell Death Mechanisms to Therapeutic Horizons.Drug design, development and therapy · 2025Review
- The potential roles of gut microbiome in porto-sinusoidal vascular disease: an under-researched crossroad.Frontiers in microbiology · 2025Review
- Causal effect of gut microbiota on venous thromboembolism: a two-sample mendelian randomization study.Thrombosis journal · 2024Article
- Inflammatory Bowel Disease and Cardiovascular Disease: An Integrative Review With a Focus on the Gut Microbiome.Cureus · 2024Review
- [New targets for the prevention and treatment of cirrhotic portal vein thrombosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The gut microbiome plays a critical role in various inflammatory conditions, and its modulation is a potential treatment option for these conditions. The role of the gut microbiome in the pathogenesis of thromboembolism has not been fully elucidated. In this review, we summarize the evidence linking the gut microbiome to the pathogenesis of arterial and venous thrombosis. In a human host, potentially pathogenic bacteria are normal residents of the human gut microbiome, but significantly outnumbered by commensal anaerobic bacteria. Several disease states with an increased risk of venous thromboembolism (VTE) are associated with an imbalance in the gut microbiome characterized by a decrease in commensal anaerobic bacteria and an increase in the abundance of pathogenic bacteria of which the most common is the gram-negative Enterobacteriaceae (ENTERO) family. Bacterial lipopolysaccharides (LPS), the glycolipids found on the outer membrane of gram-negative bacteria, is one of the links between the microbiome and hypercoagulability. LPS binds to toll-like receptors to activate endothelial cells and platelets, leading to activation of the coagulation cascade. Bacteria in the microbiome can also metabolite compounds in the diet to produce important metabolites like trimethylamine-N-oxide (TMAO). TMAO causes platelet hyperreactivity, promotes thrombus formation and is associated with cardiovascular disease. Modulating the gut microbiome to target LPS and TMAO levels may be an innovative approach for decreasing the risk of thrombosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.